News | July 15, 2013

Lariat Procedure Reduces Stroke Risk in Patients Who Cannot Tolerate Blood Thinners

Lariat Suture Device Left Atrial Appendage Occluder Stroke Risk

July 15, 2013 — Shore University Medical Center is one of only a handful of hospitals in the country offering the recent U.S. Food and Drug Administration (FDA)-approved Lariat Suture Delivery Device procedure. Electrophysiologists and interventional cardiologists perform this innovative procedure to help prevent stroke in patients who suffer from atrial fibrillation and are unable to take blood thinners.

“Atrial fibrillation is one of the most common heart rhythm problems seen in the world,” explains Dawn Calderon, D.O., FACC, chief of cardiology and director of the Adult Congenital Heart Center at Jersey Shore. “An estimated 2.7 million Americans suffer from atrial fibrillation, and these patients are five times more likely to suffer from stroke. For those who cannot tolerate traditional medications, the Lariat

Strokes typically occur when blood forms clots in the left atrial appendage (LAA), a small pouch which empties into the left atrium. Patients at high-risk for stroke are typically placed on oral anticoagulation therapy to prevent strokes; however some cannot tolerate these due to bleeding complications. In the past, these patients would require open-heart surgery. The Lariat procedure is a non-surgical option whereby the LAA is tied so clots cannot form, drastically reducing the risk of heart related stroke. Performed under general anesthesia, the procedure involves two catheters that are guided to the patient’s heart to seal the LAA with the device. Once in place, the LARIAT tightens a loop stitch around the base of the LAA, permanently sealing it off from the rest of the heart and closing it off to any blood flow.

According to Ashish Patel, M.D., electrophysiologist at Jersey Shore, “90 percent of strokes caused by atrial fibrillation originate from the LAA. The LAA provides no function, so when it is tied, the source of heart related stroke is reduced. Other benefits include less discomfort and a shorter recovery time than open heart surgery. The Lariat is truly a breakthrough for patients who can’t take blood thinners as it provides a new way to help prevent heart related stroke.”

Jersey Shore University Medical Center is one of the largest cardiovascular programs in New Jersey. Through Meridian CardioVascular Network, Jersey Shore offers the most complete, coordinated care from prevention and wellness programs to the diagnosis and treatment of heart disease to rehabilitation and recovery.

For more information:

Related Content

J&J Announces U.S. IDE Study to Evaluate Potential of New Device to Reduce Stroke Risk in Afib
News | Left Atrial Appendage (LAA) Occluders | January 18, 2018
January 18, 2018 – Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc., a worldwide
Videos | Left Atrial Appendage (LAA) Occluders | November 14, 2017
Vivek Reddy, M.D., director of cardiac arrhythmia services and professor of medicine, cardiology, Mount Sinai Hospita
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders | September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
News | Left Atrial Appendage (LAA) Occluders | April 25, 2017
AtriCure Inc. announced it has sold more than 100,000 AtriClip Left Atrial Appendage Exclusion System devices worldwide...
atricure atriclip, LAA occlusion, acc17

The AtriCure Atriclip surgical LAA occlusion device. It loops over the LAA on the outside of the heart and clips it off from the rest of the heart to prevent the formation of clots.

Feature | Left Atrial Appendage (LAA) Occluders | March 29, 2017
March 29, 2017 — For patients with...
Aegis Medical Innovations, Sierra Ligation System, U.S. clinical trial, FDA approval, LAA occluder
Technology | Left Atrial Appendage (LAA) Occluders | March 22, 2017
Aegis Medical Innovations Inc. announced that it has received Investigational Device Exemption approval from the U.S....
SentreHeart, Eclipse Surgical Device, left atrial appendage, LAA closure, first clinical use, Poland
News | Left Atrial Appendage (LAA) Occluders | October 13, 2016
SentreHeart Inc. announced this week it has treated the first patients using the Eclipse Surgical Device, which is...
Overlay Init